President Obama’s latest budget includes proposals—echoed or one-upped on the presidential-campaign trail by Bernie Sanders and Hillary Clinton—that would require pharmaceutical companies to release data on the cost of research and development (R&D) and the extent of discounts offered to insurers for each drug brought to market. Yet the key numbers already are disclosed freely—and we know how to get better value from medicines and improve their affordability to patients.

The company I lead, Lilly, discloses its annual...